Merus Announces Annual General Meeting Results

Merus Announces Annual General Meeting Results 
TORONTO, ONTARIO -- (Marketwire) -- 03/29/13 -- Merus Labs
International Inc. ("Merus") (TSX:MSL)(NASDAQ:MSLI) announces the
voting results from its Annual General Meeting of its shareholders
held in Toronto.  
A total of 11.9 million common shares representing 38.9% of Merus'
issued and outstanding common shares were represented at the meeting.
All of the shareholders present in person at the meeting voted in
favour of the items of business and the overall result of the votes,
including the votes by proxy, were as follows: 


 
     Resolution                                         For    Withheld     
     ------------------------------------------ ----------- -----------     
                                                                            
     Set Number of Directors at Six               8,649,601     106,140     
                                                                            
     Elect Elie Farah as a Director              10,158,361      31,991     
                                                                            
     Elect Ahmad Doroudian as a Director         10,158,141      32,211     
                                                                            
     Elect David Guebert as a Director            7,381,996   2,808,356     
                                                                            
     Elect Robert Pollock as a Director           7,573,336   2,617,016     
                                                                            
     Elect Joseph Rus as a Director              10,158,236      32,116     
                                                                            
     Elect Timothy Sorensen as a Director         7,570,336   2,620,016     
                                                                            
     Appoint Deloitte & Touche LLP as Auditors    7,007,702       6,505     

 
About Merus Labs International Inc.  
Merus is a specialty pharmaceutical company engaged in the
acquisition and licensing of pharmaceutical products. Merus utilizes
its expertise in pharmaceutical markets and its access to capital to
acquire and license niche branded products. Merus further enhances
the sale and distribution of these products by the introduction of a
focused marketing and promotion plan. 
Contacts:
Merus Labs International Inc.
Elie Farah
President and CEO
(416) 593-3701
efarah@meruslabs.com
 
 
Press spacebar to pause and continue. Press esc to stop.